76.7 F
San Fernando
Tuesday, Aug 16, 2022
-Advertisement-

Atara Biotherapeutics Reports Widening Loss, Adds Board Member

T-cell immunology company Atara Biotherapeutics Inc. reported its second-quarter 2021 financial results and the appointment of a cell therapy and oncology commercialization veteran to its board.Atara, based in San Francisco but with its operations in Thousand Oaks, reported net losses of $83.8 million, or -91 cents per share during the quarter, compared to $77.5 million, or -$1.14 per share, for the same period in 2020. Revenue totaled $3.9 million, up from zero a year ago.The company reported cash, cash equivalents and short-term investments of $373 million as of June 30. In a statement, the company said it believes its current cash amount will sufficiently fund its planned operations into 2023.On the same day it reported financial results, Atara also announced the appointment of Ameet Mallik to its board. Mallik is chief executive of Rafael Holdings Inc., a late-stage cancer metabolism therapeutic company.“Ameet joins us at a critical time as we advance our first-in-kind off-the-shelf allogeneic T-cell immunotherapy and anticipate our first approvals in 2022,” Pascal Touchon, Atara’s chief executive, said in a statement.Shares of Atara (ATRA) closed Tuesday up 25 cents, or 2 percent, to $12.74 on the Nasdaq

Antonio Pequeño IV
Antonio Pequeño IV
Antonio “Tony” Pequeño IV is a reporter covering health care, finance and law for the San Fernando Valley Business Journal. He specializes in reporting on some of the biggest names in the Valley’s biotechnology sector. In addition to his work with the Business Journal, Tony has reported with BuzzFeed News on the unsupervised use of Clearview AI, a controversial facial recognition technology. Tony, who also conducts freelance reporting, graduated from the USC’s Master of Science in Journalism program in 2021. He is in his fifth year as a journalist as of 2021.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-